期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

风险比在生存资料Meta分析中的应用 被引量：6

下载PDF
导出
摘要 Meta分析可增加效应量的强度，增强结果的精确性，得出更加可靠的结论，为临床提供参考的信息；同时还可分析不同研究间的差异甚至产生新的假设[1]。
作者 王权 何曦冉 蒋林 王启荣 田金徽 杨克虎
机构地区 兰州大学基础医学院循证医学中心 北京大学临床肿瘤学院 兰州大学第一临床医学院
出处 《中国循证心血管医学杂志》 2013年第6期559-560,共2页 Chinese Journal of Evidence-Based Cardiovascular Medicine
关键词 META分析 生存资料 风险比 应用 精确性
分类号 R4 [医药卫生—临床医学]
  • 相关文献

参考文献9

  • 1孙振球,徐勇勇.医学统计学[J].第1版.北京:人民卫生出版社,2002,257.
  • 2I Cbalmers. The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care[J]. Annals of the New York Academy of Sciences,1993,703: 156-65.
  • 3M Bhansali,Vaidya J,Bhatt R,et al. Chemotherapy for carcinoma of the esophagus:a comparison of evidence from meta-analyses of randomized trials and of historical control studies[J]. Annals of oncol ogy,1996,7(4):355-9.
  • 4MK Parmar,Torri V,Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints[J]. Statistics in medicine,1998,17(24):2815-34.
  • 5CHH JPT,Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011][J]. The Cochrane Collaboration, 2011.
  • 6MK Parmar, Machin D. Survival analysis: a practical approach[M]. John Wiley & Sons New York, 1995.
  • 7姜金,李伦,王晓晶,田金徽,王权,林乔.培美曲塞联合铂类对比吉西他滨联合铂类治疗晚期非小细胞肺癌的meta分析[J].中国肺癌杂志,2011,14(1):43-48. 被引量：27
  • 8JF Tierney,Stewart LA,Ghersi D,et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials,2007,8:16.
  • 9SL Spruance,Reid JE,Grace M,et al. Hazard ratio in clinical trials[J]. Antimicrobial agents and chemotherapy,2004,48(8):2787-92.

二级参考文献16

  • 1Kurup A, Hanna NH. Treatment of small cell lung cancer. Crit Rev Oncol Hematol, 2004, 52(2): 117-126.
  • 2Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346(2): 92-98.
  • 3Calvert H. An overview of folate metabolism: Features relevant to the action and toxicities ofantifolate agents. Semin Oncol, 1999, 26(2 Suppl16): 3-10.
  • 4Cochrane Handbook for Systematic Reviews of Interventions Version S.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. [www. cochrane-handbook.org/]. Accessed 10 March 2009.
  • 5Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-ceU lung cancer.J Clin Oncol, 2009, 27( 19): 3217-3224.
  • 6Scagliotti GV, Parikh P, Von PawelJ, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008, 26(21): 3543-3551.
  • 7Ramalingam S, Belani CP. State-of-the-art chemotherapy for advanced non- small cell lung cancer. Semin O ncol, 2004, 31 (1 suppl 1 ): 68-74.
  • 8Cho KH, Song YB, Choi IS, et al. A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer. Jpn J Clin Oncol, 2006, 36 (1): 50-54.
  • 9Crino L, Mosconi AM, Scaqliotti G, et al. Gemcitabine as second-line treatment for advanced non-small-ceU lung cancer: A phase II trial. J Clin Oncol, 1999, 17(7): 2081.
  • 10Curtin NJ, Hughes AN. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol, 2001, 2(5): 298-306.

共引文献26

同被引文献39

  • 1胡正祥.人工血管在血透通路中的应用[J].中华血管外科杂志,2019,4(4):257-260. 被引量：3
  • 2王玉平,吕军,陈咏梅,汤显斌,谢飞,张吉才,冯景.多基因甲基化对散发性乳腺癌的诊断价值[J].郧阳医学院学报,2010,29(6):491-499. 被引量：2
  • 3Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints[J]. Stat Med, 1998,17(24):2815-2834.
  • 4Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: An overview of the randomized trials[J]. Prog Cardiovasc Dis, 1985,27(5):335-371.
  • 5Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials, 2007,8:16.
  • 6Medical Research Council Working Party. A trial of Ro 03-8799 (Pimonidazole) in carcinoma of the uterine cervix: An interim report from the medical research council working party on advanced carcinoma of the cervix[J]. Radiother Oncol,1993,26(2):93-103.
  • 7International collaboration of trialists on behalf of the medical research council Advanced bladder cancer working party. Neoadjuvant Cisplatin, Methotrexate, and Vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. International collaboration of trialists[J]. Lancet,1999,354(9178):533-540.
  • 8Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, et al. Prognostic significance of transforming growth factor beta (TGF-beta) signaling axis molecules and E-cadherin in colorectal cancer[J]. Tumour Biol, 2012,33(4):1005-1014.
  • 9黄建成,姜宗弟,钱若筠,罗兴.七氟醚在全麻手术中的应用[J].新疆医学,1997,27(4):198-200. 被引量：1
  • 10霍岩,程刚.消癌平联合化疗治疗晚期胃癌的临床观察[J].中国社区医师（医学专业）,2009,11(18):138-138. 被引量：7

引证文献6

二级引证文献28

中国循证心血管医学杂志
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部